These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 33441154)

  • 1. New approaches to symptomatic treatments for Alzheimer's disease.
    Cummings J
    Mol Neurodegener; 2021 Jan; 16(1):2. PubMed ID: 33441154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
    Cummings J
    J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia.
    Deardorff WJ; Grossberg GT
    Handb Clin Neurol; 2019; 165():5-32. PubMed ID: 31727229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease.
    Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL
    Expert Opin Emerg Drugs; 2024 Sep; 29(3):289-303. PubMed ID: 38822731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychiatric Aspects of Alzheimer Dementia: From Mechanism to Treatment.
    Nowrangi MA
    Psychiatr Clin North Am; 2020 Jun; 43(2):383-397. PubMed ID: 32439028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
    Cummings J; Zhong K
    Clin Pharmacol Ther; 2015 Nov; 98(5):483-5. PubMed ID: 26206713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropsychiatric symptoms and quality of life in Spanish patients with Alzheimer's disease during the COVID-19 lockdown.
    Lara B; Carnes A; Dakterzada F; Benitez I; Piñol-Ripoll G
    Eur J Neurol; 2020 Sep; 27(9):1744-1747. PubMed ID: 32449791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development.
    Burke SL; Maramaldi P; Cadet T; Kukull W
    Arch Gerontol Geriatr; 2016; 65():231-8. PubMed ID: 27111252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects.
    Dietlin S; Soto M; Kiyasova V; Pueyo M; de Mauleon A; Delrieu J; Ousset PJ; Vellas B
    J Alzheimers Dis; 2019; 70(1):25-34. PubMed ID: 31127783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
    J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroanatomical associations of depression, anxiety and apathy neuropsychiatric symptoms in patients with Alzheimer's disease.
    Mohamed Nour AEA; Jiao Y; Teng GJ;
    Acta Neurol Belg; 2021 Dec; 121(6):1469-1480. PubMed ID: 32319015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-pharmacological and pharmacological treatment of the cognitive and behavioral symptoms of Alzheimer disease.
    Zec RF; Burkett NR
    NeuroRehabilitation; 2008; 23(5):425-38. PubMed ID: 18957729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.
    Koenig AM; Arnold SE; Streim JE
    Curr Psychiatry Rep; 2016 Jan; 18(1):3. PubMed ID: 26695173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of neuropsychiatric symptoms and psychiatric disorders in mild Alzheimer's disease and mild cognitive impairment subtypes.
    Di Iulio F; Palmer K; Blundo C; Casini AR; Gianni W; Caltagirone C; Spalletta G
    Int Psychogeriatr; 2010 Jun; 22(4):629-40. PubMed ID: 20367890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline.
    Johansson M; Stomrud E; Johansson PM; Svenningsson A; Palmqvist S; Janelidze S; van Westen D; Mattsson-Carlgren N; Hansson O
    Biol Psychiatry; 2022 Jul; 92(1):34-43. PubMed ID: 35346458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease.
    Zhang F; Qin Y; Xie L; Zheng C; Huang X; Zhang M
    J Neural Transm (Vienna); 2019 Aug; 126(8):1081-1094. PubMed ID: 31292734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Closing-in is related to apathy in Alzheimer's disease patients.
    Grossi D; de Lucia N; Trojano L
    J Alzheimers Dis; 2015; 43(3):849-55. PubMed ID: 25125462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.